RPL3 and malignant colon neoplasm: Combined NP treatment results are more effective in inducing apoptosis in p53 null cancer cells than 5-FU or rpL3 alone, thereby providing a proof of principle on molecular-based individualized target therapy for the treatment of human colon cancer lacking p53 and rpL3.